NULOJIX

NDC 0003-0371 · E.R. Squibb & Sons, L.L.C.

Generic nameBELATACEPT

Dosage formINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

RouteINTRAVENOUS

Active ingredient(s)BELATACEPT

Strength250 mg/1

Pharmacologic classCD80-directed Antibody Interactions [MoA], CD86-directed Antibody Interactions [MoA], Selective T Cell Costimulation Blocker [EPC], T Lymphocyte Costimulation Activity Blockade [PE]

Marketing categoryBLA

Packages

0003-0371-13 — 1 VIAL, SINGLE-USE in 1 CARTON (0003-0371-13) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-USE

Billed under HCPCS

J0485 — Injection, belatacept, 1 mg Medicare Part B payment limit (ASP + 6%): $3.88

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.

Read from: FDA National Drug Code Directory, product.txt and package.txt (accessdata.fda.gov/cder/ndctext.zip) — Snapshot retrieved 2026-08-24, loaded 2026-08-24; CMS Medicare Part B Drug Average Sales Price (ASP) Pricing Files (cms.gov/medicare/payment/part-b-drugs/asp-pricing-files) -- the NDC-HCPCS crosswalk and Part B payment limit files — 2026 Q4 (October 2026 release). All data sources · How to read the labels

Current data releases:ICD-10-CM FY2027 · ICD-10-PCS FY2027 · HCPCS October 2026 · MS-DRG v44 · Medicare Code Editor v44.0 · NCCI PTP Q4 2026 · MUE Q4 2026 · NCD code lists 2026-01 · LCD export September 28, 2026 · All releases and sources